Table 1 Summary of the results of NASBA-OC testing of different clinical samples.
Clinical Sample | Number of Samples NASBA-OC positive | Number of Samples NASBA-OC negative |
|---|---|---|
Blood samples healthy controls from Sudan (n = 50) | 0 | 50 |
Blood samples confirmed VL cases from Sudan (n = 30) | 28 | 2 |
Skin biopsies of patients with other skin diseases from The Netherlands (n = 5) | 0 | 5 |
Skin biopsies of patients with confirmed CL from Suriname (n = 27) | 27 | 0 |
Skin biopsies of patients with confirmed CL from Brazil (n = 43) | 42 | 1 |
Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) estimated at a 95% confidence interval (95% CI) of the NASBA-OC on different clinical samples | ||
NASBA-OC employed on blood samples | ||
Sensitivity | 93.3% (95% CI: 76.5% - 98.8%) | |
Specificity | 100% (95 CI: 91.1% - 100%) | |
PPV | 100% (95% CI: 85.0 - 100%) | |
NPV | 96.2% (95 CI: 85.7% - 99.3%) | |
NASBA-OC employed on skin biopsies | ||
Sensitivity | 98.6% (95% CI: 91.2% - 99.9%) | |
Specificity | 100% (95% CI: 46.3% - 100%) | |
PPV | 100% (95% CI: 93.4% - 100%) | |
NPV | 83.3% (95% CI: 36.5% - 99.1%) | |